EMA gives thumbs-down to GSK's multiple myeloma drug, PTC's Duchenne candidate
Multiple myeloma drug Blenrep and Duchenne muscular dystrophy therapeutic Translarna did not make the European Medicines Agency’s cut for full marketing authorization, the agency announced Friday.
The EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended against renewing the conditional marketing authorization for GSK’s Blenrep (belantamab mafodotin) for late-stage bone marrow cancer. The drug first received conditional marketing authorization in 2020. Blenrep is used for patients with worsening cancer who have had at least four previous treatments.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.